{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:21:57Z","timestamp":1781623317371,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13760-023-02251-9","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:24:43Z","timestamp":1680607483000},"page":"1429-1437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson\u2019s disease"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-3340","authenticated-orcid":false,"given":"Fardin","family":"Nabizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sodeifian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhosein","family":"Kargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"6","key":"2251_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML de Lau","year":"2006","unstructured":"de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535. https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9","journal-title":"Lancet Neurol"},{"issue":"12","key":"2251_CR2","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol 15(12):1257\u20131272. https:\/\/doi.org\/10.1016\/S1474-4422(16)30230-7","journal-title":"Lancet Neurol"},{"issue":"11","key":"2251_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.20609","volume":"20","author":"DM Huse","year":"2005","unstructured":"Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson\u2019s disease. Mov Disord 20(11):1449\u20131454. https:\/\/doi.org\/10.1002\/mds.20609","journal-title":"Mov Disord"},{"issue":"S1","key":"2251_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 139(S1):318\u2013324. https:\/\/doi.org\/10.1111\/jnc.13691","journal-title":"J Neurochem"},{"key":"2251_CR5","doi-asserted-by":"crossref","unstructured":"Kouli A, Torsney KM, Kuan WL. Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications Copyright: The Authors.; 2018.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"2251_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009258","author":"DW Dickson","year":"2012","unstructured":"Dickson DW (2012) Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a009258","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6645","key":"2251_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M (1997) \u03b1-Synuclein in Lewy bodies. Nature 388(6645):839\u2013840. https:\/\/doi.org\/10.1038\/42166","journal-title":"Nature"},{"key":"2251_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nature12125","author":"J Burr\u00e9","year":"2013","unstructured":"Burr\u00e9 J, Vivona S, Diao J, Sharma M, Brunger AT, S\u00fcdhof TC (2013) Properties of native brain \u03b1-synuclein. Nature. https:\/\/doi.org\/10.1038\/nature12125","journal-title":"Nature"},{"issue":"2","key":"2251_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160\u2013164. https:\/\/doi.org\/10.1038\/ncb748","journal-title":"Nat Cell Biol"},{"issue":"10","key":"2251_CR10","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that & #x3b1;-synuclein oligomers are toxic. Proc Natl Acad Sci 108(10):4194\u20134199. https:\/\/doi.org\/10.1073\/pnas.1100976108","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2251_CR11","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/j.1582-4934.2011.01507.x","volume":"16","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16(6):1166\u20131183. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01507.x","journal-title":"J Cell Mol Med"},{"issue":"13","key":"2251_CR12","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1096\/fj.06-6092com","volume":"20","author":"T Duka","year":"2006","unstructured":"Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL et al (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. Faseb j 20(13):2302\u20132312. https:\/\/doi.org\/10.1096\/fj.06-6092com","journal-title":"Faseb j"},{"issue":"9","key":"2251_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Lee VMY, Trojanowski JQ (2013) Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci 14(9):626\u2013636. https:\/\/doi.org\/10.1038\/nrn3549","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2251_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.expneurol.2010.06.017","volume":"225","author":"J Wills","year":"2010","unstructured":"Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia. Exp Neurol 225(1):210\u2013218. https:\/\/doi.org\/10.1016\/j.expneurol.2010.06.017","journal-title":"Exp Neurol"},{"issue":"2","key":"2251_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.21192","volume":"62","author":"A Goris","year":"2007","unstructured":"Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J et al (2007) Tau and alpha-synuclein in susceptibility to, and dementia in Parkinson\u2019s disease. Ann Neurol 62(2):145\u2013153. https:\/\/doi.org\/10.1002\/ana.21192","journal-title":"Ann Neurol"},{"issue":"21","key":"2251_CR16","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1212\/01.wnl.0000312515.52545.51","volume":"70","author":"C Marras","year":"2008","unstructured":"Marras C, Lang A (2008) Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 70(21):1996\u20132003. https:\/\/doi.org\/10.1212\/01.wnl.0000312515.52545.51","journal-title":"Neurology"},{"issue":"4","key":"2251_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jnnp-2012-303455","volume":"84","author":"C Marras","year":"2013","unstructured":"Marras C, Lang A (2013) Parkinson\u2019s disease subtypes: lost in translation? Journal of Neurology. Neurosurg Psychiat 84(4):409. https:\/\/doi.org\/10.1136\/jnnp-2012-303455","journal-title":"Neurosurg Psychiat"},{"issue":"11","key":"2251_CR18","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s10072-018-3522-z","volume":"39","author":"D Aleksovski","year":"2018","unstructured":"Aleksovski D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39(11):1971\u20131976. https:\/\/doi.org\/10.1007\/s10072-018-3522-z","journal-title":"Neurol Sci"},{"issue":"10","key":"2251_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaneurol.2013.3861","volume":"70","author":"JH Kang","year":"2013","unstructured":"Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid \u03b2-amyloid 1\u201342, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277\u20131287. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3861","journal-title":"JAMA Neurol"},{"issue":"5","key":"2251_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.14336\/AD.2019.0112","volume":"10","author":"YH Elizabeth Qian","year":"2019","unstructured":"Elizabeth Qian YH (2019) Aging Dis 10(5):1130\u20131139","journal-title":"Aging Dis"},{"issue":"5","key":"2251_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/jnnp-2012-303808","volume":"84","author":"G Alves","year":"2013","unstructured":"Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF et al (2013) Cerebrospinal fluid amyloid-\u03b2 and phenotypic heterogeneity in de novo Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 84(5):537\u2013543. https:\/\/doi.org\/10.1136\/jnnp-2012-303808","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2251_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00702-011-0736-0","volume":"119","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA (2012) CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm (Vienna) 119(4):455\u2013456. https:\/\/doi.org\/10.1007\/s00702-011-0736-0","journal-title":"J Neural Transm (Vienna)"},{"key":"2251_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/S00415-014-7513-6","author":"T Herman","year":"2014","unstructured":"Herman T, Weiss A, Brozgol M, Giladi N, Hausdorff JM (2014) Gait and balance in Parkinson\u2019s disease subtypes: objective measures and classification considerations. J Neurol. https:\/\/doi.org\/10.1007\/S00415-014-7513-6","journal-title":"J Neurol"},{"issue":"5","key":"2251_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC (2013) How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson\u2019s disease rating scale: comparison with the unified Parkinson\u2019s disease rating scale. Movem Disord Off J Movem Disord Soc 28(5):668\u2013670. https:\/\/doi.org\/10.1002\/mds.25383","journal-title":"Movem Disord Off J Movem Disord Soc"},{"issue":"9","key":"2251_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/MDS.20513","volume":"20","author":"GA Kang","year":"2005","unstructured":"Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson\u2019s disease in a central California population-based study. Mov Disord 20(9):1133\u20131142. https:\/\/doi.org\/10.1002\/MDS.20513","journal-title":"Mov Disord"},{"key":"2251_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06110-y","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh F, Sodeifian F, Pirahesh K (2022) Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson\u2019s disease. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-022-06110-y","journal-title":"Neurol Sci"},{"issue":"7","key":"2251_CR27","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1007\/s10072-022-05952-w","volume":"43","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh F, Pirahesh K, Khalili E (2022) Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson\u2019s disease. Neurol Sci 43(7):4193\u20134201. https:\/\/doi.org\/10.1007\/s10072-022-05952-w","journal-title":"Neurol Sci"},{"issue":"10","key":"2251_CR28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L et al (1990) Variable expression of Parkinson\u2019s disease: a base-line analysis of the DAT ATOP cohort. Neurology 40(10):1529","journal-title":"Neurology"},{"issue":"6","key":"2251_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","volume":"131","author":"J-H Kang","year":"2016","unstructured":"Kang J-H, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s Progression Markers Initiative study. Acta Neuropathol 131(6):935\u2013949","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2251_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/mds.25495","volume":"28","author":"KD van Dijk","year":"2013","unstructured":"van Dijk KD, Persichetti E, Chiasserini D, Eusebi P, Beccari T, Calabresi P et al (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson\u2019s disease. Mov Disord 28(6):747\u2013754","journal-title":"Mov Disord"},{"issue":"4","key":"2251_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.parkreldis.2014.01.011","volume":"20","author":"S Mondello","year":"2014","unstructured":"Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A (2014) CSF \u03b1-synuclein and UCH-L1 levels in Parkinson\u2019s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20(4):382\u2013387","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2251_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053250","volume":"8","author":"M Wennstr\u00f6m","year":"2013","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Bostr\u00f6m F et al (2013) Low CSF levels of both \u03b1-synuclein and the \u03b1-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8(1):e53250","journal-title":"PLoS ONE"},{"issue":"4","key":"2251_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"K Marek","year":"2011","unstructured":"Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T et al (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629\u2013635","journal-title":"Prog Neurobiol"},{"issue":"3","key":"2251_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","volume":"9","author":"L Parnetti","year":"2013","unstructured":"Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O et al (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9(3):131\u2013140","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2251_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","volume":"7","author":"MJ Park","year":"2011","unstructured":"Park MJ, Cheon S-M, Bae H-R, Kim S-H, Kim JW (2011) Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson\u2019s disease. J Clin Neurol 7(4):215\u2013222","journal-title":"J Clin Neurol"},{"issue":"3","key":"2251_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","volume":"26","author":"F Tateno","year":"2012","unstructured":"Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26(3):213\u2013216","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"2251_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ajpath.2013.12.007","volume":"184","author":"T Stewart","year":"2014","unstructured":"Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B et al (2014) Cerebrospinal fluid \u03b1-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 184(4):966\u2013975","journal-title":"Am J Pathol"},{"key":"2251_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fneur.2018.00560","volume":"9","author":"M Dolatshahi","year":"2018","unstructured":"Dolatshahi M, Pourmirbabaei S, Kamalian A, Ashraf-Ganjouei A, Yaseri M, Aarabi MH (2018) Longitudinal alterations of alpha-synuclein, amyloid beta, total, and phosphorylated tau in cerebrospinal fluid and correlations between their changes in Parkinson\u2019s disease. Front Neurol 9:560","journal-title":"Front Neurol"},{"issue":"19","key":"2251_CR39","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","volume":"89","author":"B Mollenhauer","year":"2017","unstructured":"Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ et al (2017) Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89(19):1959\u20131969","journal-title":"Neurology"},{"issue":"3","key":"2251_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mds.27284","volume":"33","author":"N Abbasi","year":"2018","unstructured":"Abbasi N, Mohajer B, Abbasi S, Hasanabadi P, Abdolalizadeh A, Rajimehr R (2018) Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson\u2019s disease. Mov Disord 33(3):431\u2013439","journal-title":"Mov Disord"},{"issue":"10","key":"2251_CR41","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M et al (2017) Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 32(10):1389\u20131400","journal-title":"Mov Disord"},{"key":"2251_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.parkreldis.2018.10.018","volume":"61","author":"T Schirinzi","year":"2019","unstructured":"Schirinzi T, Sancesario GM, Di Lazzaro G, Biticchi B, Colona VL, Mercuri NB et al (2019) CSF \u03b1-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients. Parkinsonism Relat Disord 61:203\u2013206","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"2251_CR43","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.parkreldis.2015.04.027","volume":"21","author":"AL Stav","year":"2015","unstructured":"Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T (2015) Amyloid-\u03b2 and \u03b1-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson\u2019s disease. Parkinsonism Relat Disord 21(7):758\u2013764","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"2251_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/bmm.15.107","volume":"10","author":"L Parnetti","year":"2016","unstructured":"Parnetti L, Cicognola C, Eusebi P, Chiasserini D (2016) Value of cerebrospinal fluid \u03b1-synuclein species as biomarker in Parkinson\u2019s diagnosis and prognosis. Biomark Med 10(1):35\u201349","journal-title":"Biomark Med"},{"issue":"1","key":"2251_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","volume":"11","author":"A Lleo","year":"2015","unstructured":"Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N et al (2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol 11(1):41\u201355","journal-title":"Nat Rev Neurol"},{"key":"2251_CR46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2018.01.018","volume":"49","author":"MG F\u00f8rland","year":"2018","unstructured":"F\u00f8rland MG, \u00d6hrfelt A, Dalen I, Tysnes O-B, Blennow K, Zetterberg H et al (2018) Evolution of cerebrospinal fluid total \u03b1-synuclein in Parkinson\u2019s disease. Parkinsonism Relat Disord 49:4\u20138","journal-title":"Parkinsonism Relat Disord"},{"key":"2251_CR47","doi-asserted-by":"crossref","unstructured":"Nabizadeh F, Pirahesh K, Valizadeh P (2022). REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson\u2019s disease: a cross-sectional and longitudinal study. J Neurol 1\u201310","DOI":"10.1007\/s13760-023-02251-9"},{"issue":"10","key":"2251_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.biopsych.2008.02.016","volume":"64","author":"L Parnetti","year":"2008","unstructured":"Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D\u2019Amore C et al (2008) Cerebrospinal fluid biomarkers in Parkinson\u2019s disease with dementia and dementia with Lewy bodies. Biol Psychiat 64(10):850\u2013855","journal-title":"Biol Psychiat"},{"issue":"1","key":"2251_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/gps.2496","volume":"26","author":"M Andersson","year":"2011","unstructured":"Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int J Geriatr Psychiatry 26(1):100\u2013105","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1\u20132","key":"2251_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000353442","volume":"36","author":"M Nutu","year":"2013","unstructured":"Nutu M, Zetterberg H, Londos E, Minthon L, N\u00e4gga K, Blennow K et al (2013) Evaluation of the cerebrospinal fluid amyloid-\u03b21-42\/amyloid-\u03b21-40 ratio measured by alpha-LISA to distinguish Alzheimer\u2019s disease from other dementia disorders. Dement Geriatr Cogn Disord 36(1\u20132):99\u2013110","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"2251_CR51","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3233\/JAD-160698","volume":"55","author":"M Buongiorno","year":"2017","unstructured":"Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lome\u00f1a F et al (2017) Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-\u03b2 and Tau in Parkinson\u2019s disease. J Alzheimers Dis 55(3):1261\u20131272","journal-title":"J Alzheimers Dis"},{"issue":"15","key":"2251_CR52","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/mds.23287","volume":"25","author":"TJ Montine","year":"2010","unstructured":"Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C et al (2010) CSF A\u03b242 and tau in Parkinson\u2019s disease with cognitive impairment. Mov Disord 25(15):2682\u20132685","journal-title":"Mov Disord"},{"key":"2251_CR53","first-page":"369","volume":"8","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"2014","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garcia-Martin E, Ag\u00fandez JA (2014) Cerebrospinal fluid biochemical studies in patients with Parkinson\u2019s disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci 8:369","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"2251_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.22311","volume":"69","author":"M Shi","year":"2011","unstructured":"Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69(3):570\u2013580","journal-title":"Ann Neurol"},{"issue":"1","key":"2251_CR55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","volume":"20","author":"MK Herbert","year":"2014","unstructured":"Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB et al (2014) CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20(1):112\u2013115","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"2251_CR56","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/mds.22594","volume":"24","author":"Y Compta","year":"2009","unstructured":"Compta Y, Mart\u00ed MJ, Ibarretxe-Bilbao N, Junqu\u00e9 C, Valldeoriola F, Munoz E et al (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson\u2019s disease. Move Disord Off J Movem Disord Soc 24(15):2203\u20132210","journal-title":"Move Disord Off J Movem Disord Soc"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02251-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-023-02251-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-023-02251-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T09:36:08Z","timestamp":1689154568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-023-02251-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2251"],"URL":"https:\/\/doi.org\/10.1007\/s13760-023-02251-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Since the data in this paper were obtained from the PPMI database (ppmi.loni.usc.edu), it does not include any research involving human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This manuscript has been approved for publication by all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}